Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Parkinson Disease: early-phase trial registry
135 of 298 indexed Parkinson Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #31 of 28,707 conditions by registered trial count.
298 US clinical trials · 135 currently recruiting · #31 of 28,707 conditions by registered trial count
Parkinson Disease: 298 US clinical trials tracked, 135 recruiting.
Parkinson Disease is the subject of 298 registered US clinical trials on ClinicalTrials.gov, 135 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 66 in Phase 1-2 (earlier-stage). The most active sponsor is University of Minnesota, running 10 of these trials.
Enrollment posture brief
Registry condition parkinson-disease
OPEN 135 | RECR 45% | LATE 21 | EARLY 66 | RANK #31 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Parkinson Disease lists 135 open slots (45% of 298 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Parkinson Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Parkinson Disease is recruiting above its size-band peers.
135 of 298 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Parkinson Disease trials is spread across many organizations.
University of Minnesota accounts for 10 of 298 trials (3.4%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Parkinson Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 298 trials that report a genuine target (sentinel values excluded). 207 of those (69.5%) plan for fewer than 100 participants.
-
Parkinson Disease research is mostly interventional.
226 interventional and 72 observational studies make up this index (75.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
298 total, page 2 of 6
Cognitive Decline Following Deep Brain Stimulation
Medical University of South Carolina
NCT05822388
Cortical-Basal Ganglia Speech Networks
Massachusetts General Hospital
NCT04286308
Neurophysiology of Reward Signaling in Parkinson's Disease
Vanderbilt University Medical Center
NCT07409207
Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment
Vanderbilt University Medical Center
NCT04715984
Vestibular and Cortical Contributions to Transitions in Freezing of Gait in Parkinson's Disease
University of Minnesota
NCT06506058
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Vanderbilt University Medical Center
NCT05357612
Understanding Motivation in Parkinson's Patients Through Neurophysiology
University of California, San Francisco
NCT05065151
High-intensity Interval Circuit Training in People With Parkinson Disease
Pacific Northwest University of Health Sciences
NCT06576817
Parkinson's Disease Biomarkers in Nerve Cells in the Gut
Weill Medical College of Cornell University
NCT05347407
Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
University of Minnesota
NCT05893186
Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing
Oregon Health and Science University
NCT05818189
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
University of Minnesota
NCT06467461
Psilocybin Therapy for Depression in Parkinson's Disease
Joshua Woolley, MD, PhD
NCT06455293
TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD
Oregon Health and Science University
NCT06815302
Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control
Jorge Gonzalez-Martinez
NCT07056361
10,000 Step Club: Community Walking Program for People with Parkinson's Disease
University of Nevada, Las Vegas
NCT06605183
Neurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease
University of Florida
NCT06911229
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
Vanderbilt University Medical Center
NCT01734122
Dance and Energy Expenditure Among Adults With Parkinson's
Northeastern University
NCT06425731
Virtual Cycling Environments for Persons With Parkinson Disease
Rutgers, The State University of New Jersey
NCT04804202
Drug Discovery for Parkinson's With Mutations in the GBA Gene
New York Stem Cell Foundation Research Institute
NCT05536388
Blood Pressure Effects on Cognition and Brain Blood Flow in PD
University of California, San Diego
NCT05400174
Apathy in Parkinson Disease TMS Study
University of North Carolina, Chapel Hill
NCT06087926
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
Northwestern University
NCT04664634
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
University of Alabama at Birmingham
NCT06289582
CPAP for the Treatment of Supine Hypertension
Vanderbilt University Medical Center
NCT05489575
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
Gateway Institute for Brain Research
NCT05266417
Cognitive Decline Following Deep Brain Stimulation: A DBS-fMRI Study
Medical University of South Carolina
NCT06960096
First-in-Human Single and Multiple Dose of HL-400
Highlightll Pharmaceutical (USA)
NCT06997484
Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)
California State University, Northridge
NCT06538298
Neuroplasticity in Parkinson's Disease
University of Minnesota
NCT05286736
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Denali Therapeutics
NCT06602193
Action Regulation Behavioral
University of Texas Southwestern Medical Center
NCT06489483
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Prabesh Kanel
NCT07154511
Targeted Motor Learning to Improve Gait for Individuals With Parkinson Disease
University of North Carolina, Chapel Hill
NCT05864157
Evaluation of a Decision Aid for Deep Brain Stimulation Surgery for Parkinson's Disease
University of Colorado, Denver
NCT06446505
Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease
Teachers College, Columbia University
NCT06540989
Use of CereGate Therapy for Freezing of Gait in PD
CereGate
NCT05292794
Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease
Pacific Northwest University of Health Sciences
NCT06908135
Occupational Therapy Led Social Prescription for People With Parkinson Disease
Colorado State University
NCT06447207
[18F]F-DOPA Imaging in Patients With Autonomic Failure
Daniel Claassen
NCT04246437
Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
CND Life Sciences
NCT07217054
Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease
St. Louis University
NCT06859528
Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation
University of Southern California
NCT05307055
High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease
Massachusetts Institute of Technology
NCT05268887
Stimulus-Evoked Directional Field Potentials to Guide Subthalamic and Pallidal DBS for PD
University of Alabama at Birmingham
NCT06169852
Udall Project 2 Aim 2A&C
University of Minnesota
NCT05656586
Percept Transitions in FOG and PD
University of Minnesota
NCT06848205
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
Vanderbilt University Medical Center
NCT02897063
Dysarthria Management for Minor Groups
Florida State University
NCT06593860
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 35 |
| Phase 3 | 8 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Parkinson Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Parkinson Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Parkinson Disease page
298 registered trials, 135 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 135 Parkinson Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Minnesota sponsors the most Parkinson Disease trials on record, review their full trial history before evaluating a specific study. See University of Minnesota's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson Disease condition card totals 298 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.